Pulmonary drugs are medications used for treating various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and other lung infections. This class of drugs includes anti-asthmatics, bronchodilators, anti-inflammatory drugs, leukotriene antagonists, and combinations of multiple drugs. Pulmonary drugs provide relief from symptoms such as cough, wheezing, shortness of breath and improve lung capacity.

The global Pulmonary Drugs Market is estimated to be valued at US$ 3.41 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The increasing prevalence of respiratory diseases represents a major growth opportunity for pulmonary drugs market. As per WHO, respiratory diseases accounted for over 8 million deaths worldwide in 2019. The prevalence of asthma, COPD and other lung diseases is on the rise due to rising air pollution levels, growing smoking rates and aging population. For instance, as per American Lung Association data, over 25 million Americans currently suffer from asthma. Similarly, WHO reports that over 200 million people suffer from COPD globally. With limited treatment options currently available, the demand for effective pulmonary drugs is increasing rapidly. Moreover, the launch of novel drug formulations with improved efficacy and safety is further expected to drive the market growth over the forecast period. Development of personalized medications targeting specific respiratory conditions also presents lucrative opportunities.

Porter's Analysis

Threat of new entrants: The pulmonary drugs market requires substantial R&D investments and regulatory approvals, acting as entry barriers for new players.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over drug prices. However, the critical nature of pulmonary drugs limits bargaining.
Bargaining power of suppliers: Established drug manufacturers and raw material suppliers possess moderate bargaining power through their specialized expertise and resources.
Threat of new substitutes: The threat is moderate as it takes significant time and capital to develop new drug substitutes with similar efficacy and safety profiles.
Competitive rivalry: The market sees intense competition among major players introducing generic and patented drugs across multiple therapeutic categories.

SWOT Analysis
Strengths: Strong pipeline of innovative drugs to treat respiratory diseases. Growing prevalence of pulmonary conditions expands the market potential.
Weaknesses: High R&D costs and regulatory risks associated with drug development. Dependence on reimbursement policies for market growth.
Opportunities: Emerging economies provide sizable undertapped markets. Combination therapies present new avenues.
Threats: Patent expirations increase generic competition. Social stigmas may undermine diagnosis and treatment rates.

Key Takeaways
The global Pulmonary Drugs Market Growth  is expected to witness high growth over the forecast period of 2023-2030 at a CAGR of 8.1% driven by the increasing incidence of respiratory diseases including asthma and COPD. With sales estimated to surpass US$ 3.41 billion in 2023, the market is anticipated to reach over US$ 6 billion by 2030.

Regional analysis: North America currently dominates the pulmonary drugs market with the highest revenues owing to developed healthcare infrastructure and supportive reimbursement policies. However, Asia Pacific is likely to emerge as the fastest growing regional market in the coming years encouraged by growing penetration of health insurances and economic expansion in major Asian countries.

Key players: Key players operating in the pulmonary drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited. These leading companies enjoy strong brand recognition and collectively account for over 50% of the global market share.

For more insights, read- https://www.pressreleasebulletin.com/pulmonary-drugs-market-trends-size-and-share-analysis/